Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma

Sato,Masakazu; Arimoto,Takahide; Kawana,Kei; Miyamoto,Yuichiro; Ikeda,Yuji; Tomio,Kensuke; Tanikawa,Michihiro; Sone,Kenbun; Mori‑Uchino,Mayuyo; Tsuruga,Tetsushi; Nagasaka,Kazunori; Adachi,Katsuyuki; Matsumoto,Yoko; Oda,Katsutoshi; Osuga,Yutaka; Fujii,Tomoyuki

doi:10.3892/mco.2016.748

April-2016 Volume 4 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

April-2016 Volume 4 Issue 4

Full Size Image

Article Open Access

Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma

Authors:
- Masakazu Sato
- Takahide Arimoto
- Kei Kawana
- Yuichiro Miyamoto
- Yuji Ikeda
- Kensuke Tomio
- Michihiro Tanikawa
- Kenbun Sone
- Mayuyo Mori‑Uchino
- Tetsushi Tsuruga
- Kazunori Nagasaka
- Katsuyuki Adachi
- Yoko Matsumoto
- Katsutoshi Oda
- Yutaka Osuga
- Tomoyuki Fujii
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, Tokyo 1138655, Japan

Copyright: © Sato et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 492-496
|
Published online on: January 28, 2016

https://doi.org/10.3892/mco.2016.748
Expand metrics +

Abstract

The aim of the present study was to evaluate whether measuring endometrial thickness during fertility‑sparing treatment with medroxyprogesterone acetate (MPA) can be a predictive marker for effectiveness in women with endometrioid adenocarcinoma, grade 1 (EmCa, G1). A total of 32 patients with stage IA EmCa, G1 underwent treatment with MPA. Patients were <40 years of age and preferred fertility‑sparing treatment. MPA (600 mg/day) with low‑dose aspirin was administered orally for 26 weeks. Pathological evaluation was performed by total curettage at weeks 8 and 16 and by fractional curettage at week 26. Patients underwent curative surgery in case of disease progression. Endometrial thickness was measured by transvaginal ultrasonography at weeks 8 and 16. Patients who showed non‑complete response (non‑CR) had thicker endometrium than that of CR patients at weeks 8 and 16. Receiver operating characteristic analysis revealed cut‑off values of 8.3 and 4.7 mm endometrial thickness at weeks 8 and 16, respectively, for non‑CR. Endometrial thickness >5 mm at week 16 was an independent factor for prediction of non‑CR. Measurement of endometrial thickness during MPA treatment may be useful as a predictive marker for pathological response to MPA in patients with EmCa, G1.

View Figures

View References

1	Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynaecol Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
2	Park H, Seok JM, Yoon BS, Seong SJ, Kim JY, Shim JY and Park CT: Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium. Arch Gynecol Obstet. 285:473–478. 2012. View Article : Google Scholar : PubMed/NCBI
3	Kalogiannidis I and Agorastos T: Conservative management of young patients with endometrial highly-differentiated adenocarcinoma. J Obstet Gynaecol. 31:13–17. 2011. View Article : Google Scholar : PubMed/NCBI
4	Laurelli G, Di Vagno G, Scaffa C, Losito S, Del Giudice M and Greggi S: Conservative treatment of early endometrial cancer: Preliminary results of a pilot study. Gynecol Oncol. 120:43–46. 2011. View Article : Google Scholar : PubMed/NCBI
5	Bovicelli A, D'Andrilli G, Giordano A and De Iaco P: Conservative treatment of early endometrial cancer. J Cell Physiol. 228:1154–1158. 2013. View Article : Google Scholar : PubMed/NCBI
6	Morelli M, Di Cello A, Venturella R, Mocciaro R, D'Alessandro P and Zullo F: Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: Retrospective data from selected obese menopausal symptomatic women. Gynecol Endocrinol. 29:156–159. 2013. View Article : Google Scholar : PubMed/NCBI
7	Cade TJ, Quinn MA, Rome RM and Neesham D: Progestogen treatment options for early endometrial cancer. BJOG. 117:879–884. 2010. View Article : Google Scholar : PubMed/NCBI
8	Ramirez PT, Frumovitz M, Bodurka DC, Sun CC and Levenback C: Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: A literature review. Gynecol Oncol. 95:133–138. 2004. View Article : Google Scholar : PubMed/NCBI
9	Gunderson CC, Fader AN, Carson KA and Bristow RE: Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: A systematic review. Gynecol Oncol. 125:477–482. 2012. View Article : Google Scholar : PubMed/NCBI
10	Chang WH, Chen CH and Yu MH: Conservative therapy of stage I endometrial adenocarcinoma and atypical endometrial hyperplasia for the preservation of fertility. Int J Gynaecol Obstet. 92:137–138. 2006. View Article : Google Scholar : PubMed/NCBI
11	Fujiwara H, Jobo T, Takei Y, Saga Y, Imai M, Arai T, Taneichi A, Machida S, Takahashi Y and Suzuki M: Fertility-sparing treatment using medroxyprogesterone acetate for endometrial carcinoma. Oncol Lett. 3:1002–1006. 2012.PubMed/NCBI
12	Yahata T, Fujita K, Aoki Y and Tanaka K: Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod. 21:1070–1075. 2006. View Article : Google Scholar : PubMed/NCBI
13	Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, Nakanishi T, Sasaki H, Saji F, Iwasaka T, et al: Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 25:2798–2803. 2007. View Article : Google Scholar : PubMed/NCBI
14	Fujimoto A, Ichinose M, Harada M, Hirata T, Osuga Y and Fujii T: The outcome of infertility treatment in patients undergoing assisted reproductive technology after conservative therapy for endometrial cancer. J Assit Repord Genet. 31:1189–1194. 2014. View Article : Google Scholar
15	Shufaro Y, Simon A, Laufer N and Fatum M: Thin unresponsive endometrium-a possible complication of surgical curettage compromising ART outcome. J Assit Repord Genet. 25:421–425. 2008. View Article : Google Scholar
16	Yamazawa K, Hirai M, Fujito A, Nishi H, Terauchi F, Ishikura H, Shozu M and Isaka K: Fertility-preserving treatment with progestin and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod. 22:1953–1958. 2007. View Article : Google Scholar : PubMed/NCBI
17	Minaguchi T, Nakagawa S, Takazawa Y, Nei T, Horie K, Fujiwara T, Osuga Y, Yasugi T, Kugu K, Yano T, et al: Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. Cancer Lett. 248:112–122. 2007. View Article : Google Scholar : PubMed/NCBI
18	Minagawa Y, Sato S, Ito M, Onohara Y, Nakamoto S and Kigawa J: Transvaginal ultrasonography and endometrial cytology as a diagnostic schema for endometrial cancer. Gynecol Obstet Invest. 59:149–154. 2005. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles